CD274 and cervical squamous cell carcinoma: 2. Until specific recommendations are validated for endocervical adenocarcinoma, prediction of immunotherapy response criteria is identical to that for squamous cervical cancer. At present, PD-L1 immunohistochemistry (CPS of 1 or higher), as determined by the FDA approved companion test, by 22C3 clone, is recommended for pembrolizumab treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy